



May 9, 2025

CANAGLU Tablets 100mg, a sodium glucose co-transporter 2 (SGLT2) inhibitor in Thailand
Mitsubishi Tanabe Pharma Thailand now started marketing

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President, Representative Director: Akihiro Tsujimura, “MTPC”) announced today that consolidated subsidiary Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (Head Office: Bangkok) has started marketing CANAGLU® Tablets 100mg (generic name: canagliflozin, “CANAGLU”) for a SGLT2 inhibitor in Thailand on April 29, 2025.

CANAGLU®, which was discovered in Japan by MTPC, inhibits sodium glucose co-transporter 2 (SGLT2), a transporter involved in the reabsorption of glucose in the proximal renal tubules of the kidneys; suppresses the reabsorption of glucose; and promotes the excretion of excessive glucose into the urine, and as a result, lowers blood glucose.

Through licensees, CANAGLU® has been approved in more than 80 countries and regions around the world. Following Japan and Taiwan, Thailand is the third market in which CANAGLU® is sold by the Mitsubishi Tanabe Pharma Group.

The number of diabetes patients in Thailand has been increasing in recent years, and that trend is expected to continue.

MTTH has been selling products in the cardiovascular and metabolic disease areas in Thailand, which has one of the largest pharmaceutical markets in the ASEAN region, alongside Indonesia. Leveraging that foundation, taking this opportunity, MTTH will contribute to treatment of patients with type 2 diabetes mellitus.

Moving forward, Mitsubishi Tanabe Pharma Group will continue working to implement business activities that facilitate the rapid delivery of better drugs to patients around the world more quickly.

Contact:

Mitsubishi Tanabe Pharma Corporation
CEO Office PR Group
+81-6-6205-5119

■ About Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (MTTH)

Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (MTTH) was founded as a wholly-owned subsidiary of MTPC in Thailand in 2016. Along with Indonesia, Thailand has one of the largest pharmaceutical markets in the ASEAN region. MTTH sells REAGILA®, a medication

for schizophrenia, bipolar disorder and adjunctive therapy for major depressive disorder, in addition to many products for lifestyle-related diseases such as HERBESSER[®], TANATRIL[®] and TENELIA[®]. MTTH will expand its central nervous system pipeline with REMLEAS[®].